title: The safety of conization in the management of adenocarcinoma in situ of the uterine cervix.
abstract: OBJECTIVE
  To evaluate the occurrence of residual or recurrent disease after conization for adenocarcinoma in situ (AIS) of the uterine cervix.
  
  
  METHODS
  Medical records of 99 patients with a histologically diagnosis of AIS of the uterine cervix by conization between 1991 and 2008 were reviewed retrospectively.
  
  
  RESULTS
  Seventy eight of 99 patients (78.8%) had negative and 18 (18.2%) had positive resection margins of the conization specimen, and 3 (3.0%) had unknown margin status. Of the 78 patients with negative margins, 45 underwent subsequent hysterectomy and residual AIS were present in 4.4% (2/45) of patients. Ten of the 18 patients with positive margins received subsequent hysterectomy and 3 patients (30%) had residual AIS. Twenty-eight patients had conservative treatment and during the median follow-up time of 23.5 months (range, 7 to 124 months), only one patient (3.6%) had recurrent AIS and was treated with a simple hysterectomy. Eight patients became pregnant after conization, 4 of them delivered healthy babies, one had a spontaneous abortion and 3 were ongoing pregnancies.
  
  
  CONCLUSIONS
  Patients with positive resection margins after conization for AIS of the uterine cervix are significantly more likely to have residual disease. However, negative resection margin carries a lower risk for residual AIS, therefore conservative management with careful surveillance seems to be feasible in women who wish to preserve their fertility.
authors: Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine, Seoul, Korea.
authors: Mi-La
authors: ML
authors: Kim
authors: Ho-Suap
authors: HS
authors: Hahn
authors: Kyung-Taek
authors: KT
authors: Lim
authors: Ki-Heon
authors: KH
authors: Lee
authors: Hy-Sook
authors: HS
authors: Kim
authors: Sung-Ran
authors: SR
authors: Hong
authors: Tae-Jin
authors: TJ
authors: Kim
references: Gynecol Oncol. 1994 Dec;55(3 Pt 1):368-70
references: 7835776
references: Cancer Res Treat. 2008 Mar;40(1):1-5
references: 19688057
references: Vaccine. 2008 Aug 19;26 Suppl 10:K1-16
references: 18847553
references: Gynecol Oncol. 2000 Nov;79(2):207-10
references: 11063645
references: BJOG. 2001 Nov;108(11):1184-9
references: 11762660
references: Gynecol Oncol. 1994 Aug;54(2):175-9
references: 8063242
references: Gynecol Oncol. 2002 Sep;86(3):365-9
references: 12217763
references: J Gynecol Oncol. 2009 Jun;20(2):86-90
references: 19590718
references: Cancer. 2005 Mar 15;103(6):1258-64
references: 15693030
references: J Low Genit Tract Dis. 2007 Oct;11(4):223-39
references: 17917567
references: Am J Obstet Gynecol. 2009 Feb;200(2):182.e1-5
references: 19019325
references: Eur J Obstet Gynecol Reprod Biol. 2009 Jul;145(1):100-3
references: 19428171
references: Gynecol Oncol. 2000 Oct;79(1):6-10
references: 11006022
references: Gynecol Oncol. 2002 Sep;86(3):361-4
references: 12217762
references: Int J Gynecol Cancer. 2008 Jan-Feb;18(1):116-20
references: 17506846
references: Obstet Gynecol. 1992 Feb;79(2):173-8
references: 1731281
references: Obstet Gynecol. 2001 Nov;98(5 Pt 1):726-31
references: 11704160
references: Cancer. 1979 Sep;44(3):975-83
references: 476603
references: Gynecol Oncol. 2007 Jul;106(1):170-6
references: 17481701
references: Gynecol Oncol. 1999 Dec;75(3):356-60
references: 10600289
references: Am J Obstet Gynecol. 2007 Aug;197(2):195.e1-7; discussion 195.e7-8
references: 17689647
references: Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):171-7
references: 11303584
references: BJOG. 2010 Apr;117(5):615-9
references: 20156211